Literature DB >> 11508584

The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness.

F Wolfe1, T Pincus.   

Abstract

OBJECTIVE: To determine whether the level of inflammatory activity, determined by the erythrocyte sedimentation rate (ESR), changes over the longitudinal course of rheumatoid arthritis (RA); whether the level of inflammatory activity identified early in RA predicts longterm inflammatory status; and whether RA "bums out" after many years of inflammatory activity.
METHODS: A total of 21,866 consecutive ESR determinations from 1,897 patients with RA were analyzed to determine the association of inflammatory activity, as estimated by ESR, with duration of disease. Data were modeled by generalized estimating equations and random selection fractional polynomial regression models, controlling for age, sex, and calendar date.
RESULTS: In a nonlinear fashion, ESR decreased by 4 mm/h over the first 10 years of disease, remained stable over the next 25 years, and increased slightly thereafter. Patients treated more recently had lower ESR values. Patients with recent onset of RA, when stratified in quartiles of ESR, maintained their position over time.
CONCLUSION: Although ESR decreases by 4 mm/h over the first 10 years of disease, it remains stable or rises thereafter. The course of RA, as modeled by the ESR, appears to be "set" early in the disease and good and bad prognosis groups can be identified within the first 2 years. There is no evidence of general "burned out" RA or a lessening of disease activity with long duration of disease. Our findings tend to suggest that the ("usually treated") natural history of RA prior to introduction of antitumor necrosis factor agents is toward some degree of improvement in the early years. If the newer and combination therapies are indeed substantially better than what has been available, they must show a shifting of the curve downward, not just in the early years where it has occurred historically, but over the entire course of the illness.

Entities:  

Mesh:

Year:  2001        PMID: 11508584

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement.

Authors:  F Wolfe; H K Choi
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Authors:  Jana Hurnakova; Hana Hulejova; Jakub Zavada; Martin Komarc; Lucie Andres Cerezo; Herman Mann; Jiri Vencovsky; Karel Pavelka; Ladislav Senolt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

3.  Rheumatoid arthritis: should we shift the focus from "Treat to Target" to "Treat to Work?".

Authors:  Hani Almoallim; Ashraf Kamil
Journal:  Clin Rheumatol       Date:  2013-01-06       Impact factor: 2.980

4.  Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein.

Authors:  Yanping Wang; Ying Liang
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

5.  Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

6.  The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.

Authors:  M I Danila; A O Westfall; K Raman; L Chen; R J Reynolds; L B Hughes; D K Arnett; G McGwin; A J Szalai; D M van der Heijde; D Conn; L F Callahan; L W Moreland; S L Bridges
Journal:  Genes Immun       Date:  2015-07-30       Impact factor: 2.676

7.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

Authors:  A Kastbom; G Strandberg; A Lindroos; T Skogh
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

8.  ATLAS: an automated association test using probabilistically linked health records with application to genetic studies.

Authors:  Harrison G Zhang; Boris P Hejblum; Griffin M Weber; Nathan P Palmer; Susanne E Churchill; Peter Szolovits; Shawn N Murphy; Katherine P Liao; Isaac S Kohane; Tianxi Cai
Journal:  J Am Med Inform Assoc       Date:  2021-11-25       Impact factor: 7.942

9.  A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis.

Authors:  Andrew Schrepf; Chelsea M Kaplan; Eric Ichesco; Tony Larkin; Steven E Harte; Richard E Harris; Alison D Murray; Gordon D Waiter; Daniel J Clauw; Neil Basu
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

Review 10.  Biomarkers in Rheumatoid Arthritis.

Authors:  Samantha C Shapiro
Journal:  Cureus       Date:  2021-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.